Get the Stockscreener App
188.05
0.54%
0.9032
Illumina Inc stock is traded at $188.05, with a volume of 324.48K.
It is up +0.54% in the last 24 hours and up +14.54% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$187.15
Open:
$186.13
24h Volume:
324.48K
Relative Volume:
0.18
Market Cap:
$28.46B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
34.13
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
-2.89%
1M Performance:
+14.54%
6M Performance:
+32.84%
1Y Performance:
+94.07%
1-Day Range:
$184.55
$189.38
1-Week Range:
$184.02
$194.18
52-Week Range:
$88.00
$196.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
188.09 | 28.32B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
537.28 | 198.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.92 | 142.11B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
572.52 | 43.94B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
276.49 | 39.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
134.25 | 38.05B | 7.23B | 1.41B | 1.09B | 4.979 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina expands Billion Cell Atlas program with new AI drug developers - Illumina
Juno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First - Yahoo Finance
Illumina price tries to gather positive momentumForecast today16-07-2026 - Economies.com
(ILMN) Risk Channels and Responsive Allocation - Stock Traders Daily
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Illumina Inc : TD Cowen Raises Target Price t - Moomoo
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - AOL.com
ILMN5886317 Bond Profile — Key Metrics - TradingView
Video: Illumina gets behind the wheel to drive greater results - Illumina
Element Biosciences Prevails in German Patent Case Against Illumina - Business Wire
Illumina, Inc. Stock 12‑Month Price Target Raised to $165.72, Implies 13% Downside - TradingView
Bioinformatics Services Market Set for Strong Growth Driven - openPR.com
Illumina, Inc. Stock 12‑Month Price Target Raised to $162.94, Implies 14% Downside - TradingView
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina builds out C-suite with 2 new execs - MedTech Dive
Illumina Inc (ILMN) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina sets July 30 call on second-quarter 2026 results - Stock Titan
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - marketscreener.com
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer - Morgan County Citizen
Genomics Giant Illumina Taps Veteran Life Sciences Lawyer - Law.com
Illumina appoints new commercial and legal officers By Investing.com - Investing.com Nigeria
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know - Yahoo Finance
Illumina leads genomics sequencing with 90% mar... - Pluang
Illumina stock steadies as investors weigh core sequencing demand and regulatory overhang - Ad Hoc News
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat (NASDAQ:ILMN) - Seeking Alpha
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally? - Yahoo Finance
Illumina, Inc. Announces Management Appointments - marketscreener.com
Illumina Appoints Michael Sullivan and Julie Coletti to Executive Leadership Team - citybiz
Illumina appoints new commercial and legal officers - Investing.com
Illumina taps two senior leaders to steer sales and legal strategy - Stock Titan
Illumina Inc. focuses on genomics growth as a leading Nasdaq-listed life sciences company - Ad Hoc News
Align's Julie Coletti to Leave as Chief Legal and Regulatory Officer for Illumina - TradingView
Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results - Yahoo Finance
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Illumina (ILMN) Jumps On Earnings And Guidance As Valuation Questions Remain - Yahoo Finance
Illumina (ILMN) Is Up 9.1% After Raising EPS Outlook On Revenue Beat Has The Bull Case Changed? - Yahoo Finance
Bifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform - BioSpace
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Illumina (ILMN) Lifts Full Year EPS Outlook After Revenue Beat - Yahoo Finance
David P. King elected to Illumina's Board of Directors - AOL.com
Price to earnings forward of Illumina, Inc. – EUROTLX:4ILMN - TradingView
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Illumina Inc focuses on sequencing platform innovation as investors weigh long-term growth prospects - Ad Hoc News
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Illumina stock stays tied to its sequencing business. Investors watch the next filing. - Ad-hoc-news.de
Illumina Looks To Duck DNA Rival's Renewed Antitrust Case - Law360
Weekly Recap: Axelios challenges Illumina and Guggenheim lifts ILMN target to $200 - TradingView
Illumina, Inc. (ILMN) Stock Analysis: Navigating Potential Downsides Amidst 33.82% ROE - DirectorsTalk Interviews
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR - GlobeNewswire Inc.
iSeq 100 System from Illumina Inc.compact benchtop sequencer targets cost-conscious US labs - Ad-hoc-news.de
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):